12 completed, 1 recruiting. 13 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 13 | Completed 12, Recruiting 1 |
| Phase 2 | 7 | Completed 7 |
Follow Diabetic Nephropathy: new trials by email Literature Review of Diabetic Nephropathy trials Research Report on Diabetic Nephropathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Human Umbilical Cord Mesenchymal Stem Cell Injection for Diabetic Nephropathy UC-MSCs, Placebo - Diabetic Nephropathy | Phase 1 | Recruiting | Tongji Hospital | 15 | 2026-03-25 | 2026-09-16 |
| Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC73077 in Healthy Subjects HEC73077 tablets, HEC73077 placebo tablets - Diabetic Nephropathy | Phase 1 | Completed | Sunshine Lake Pharma Co., Ltd. | 138 | 2021-05-24 | 2023-04-12 |
| Safety, Tolerability and Pharmacokinetic Study of MT-3995 at a Low Dose in Subjects With Diabetic Nephropathy MT-3995, Placebo - Diabetic Nephropathy | Phase 1 / Phase 2 | Completed | Tanabe Pharma Corporation | 31 | 2014-07-01 | 2015-09-16 |
| A Study to Learn How Finerenone (BAY94-8862) Moves Into, Through and Out of the Body, How it Affects the Body, and How Safe it is in Adult Participants With Different Degrees of Reduced Liver Function and in Healthy Participants With Similar Age, Weight and Gender Distribution Finerenone (BAY94-8862) - Worsening Chronic Heart Failure, Diabetic Nephropathy | Phase 1 | Completed | Bayer | 27 | 2014-03-25 | 2021-07-16 |
| Safety, Tolerability and Pharmacokinetic Study of MT-3995 in Subjects With Diabetic Nephropathy MT-3995-Low, MT-3995-High, Placebo - Diabetic Nephropathy | Phase 1 / Phase 2 | Completed | Tanabe Pharma Corporation | 51 | 2013-07-01 | 2015-01-27 |
| Safety and Efficacy of Mesenchymal Precursor Cells in Diabetic Nephropathy Mesenchymal Precursor Cells (MPCs) - Diabetic Nephropathy, Type 2 Diabetes | Phase 1 / Phase 2 | Completed | Mesoblast, Ltd. | 30 | 2013-07-01 | 2016-10-14 |
| Study of LY3016859 in Participants With Diabetic Nephropathy Placebo, LY3016859 - Diabetic Nephropathy | Phase 1 / Phase 2 | Completed | Eli Lilly and Company | 60 | 2013-03-01 | 2019-09-19 |
| Safety, Tolerability, and Pharmacokinetics (PK) of CTP-499 CTP-499 - Diabetic Nephropathy | Phase 1 | Completed | Concert Pharmaceuticals | 38 | 2011-03-01 | 2011-10-26 |
| Effect of Sevelamer Carbonate on Oxidative Stress in Patients With Diabetic Nephropathy Sevelamer Carbonate, Calcium Carbonate - Diabetic Nephropathy | Phase 1 | Completed | Icahn School of Medicine at Mount Sinai | 20 | 2009-06-01 | 2011-11-18 |
| Phase 1 Study of FG-3019 in Subjects With Type 1 or Type 2 Diabetes Mellitus and Diabetic Nephropathy FG-3019 - Diabetes Mellitus, Diabetic Nephropathy | Phase 1 | Completed | Kyntra Bio | 38 | 2008-03-01 | 2019-08-02 |
| Multiple Dose Trial of Anti-glycation Agent GLY-230 in Healthy and Diabetic Subjects GLY-230, Placebo - Diabetic Nephropathy | Phase 1 / Phase 2 | Completed | Glycadia | 42 | 2007-02-01 | 2016-02-10 |
| Pirfenidone: A New Drug to Treat Kidney Disease in Patients With Diabetes Pirfenidone - Diabetes Mellitus, Diabetic Nephropathy | Phase 1 / Phase 2 | Completed | Sharma, Kumar, M.D. | 77 | 2003-06-01 | 2009-11-04 |
| Soy Protein in Early Diabetic Nephropathy soy protein - Diabetic Nephropathy, Diabetes Mellitus | Phase 1 / Phase 2 | Completed | National Center for Complementary and Integrative Health (NCCIH) | 2001-07-01 | 2006-08-18 |
Diabetic Nephropathies (13) · Diabetes Mellitus (3) · Diabetes Mellitus, Type 2 (2) · Kidney Diseases (2) · Diabetes Mellitus, Type 1 (1) · Metabolic Diseases (1) · Proteinuria (1) · Renal Insufficiency, Chronic (1)
Diabetes Complications (13) · Endocrine System Diseases (13) · Female Urogenital Diseases (13) · Female Urogenital Diseases and Pregnancy Complications (13) · Male Urogenital Diseases (13) · Urogenital Diseases (13) · Urologic Diseases (13) · Kidney Diseases (11) · Diabetes Mellitus (10) · Glucose Metabolism Disorders (4) · Nutritional and Metabolic Diseases (4) · Metabolic Diseases (3) · Pathological Conditions, Signs and Symptoms (2) · Autoimmune Diseases (1) · Chronic Disease (1)
1-(5-hydroxyhexyl)-3,7-dimethylxanthine (1) · 2-(3-chlorophenylamino)phenylacetic acid (1) · Calcium Carbonate (1) · Sevelamer (1) · Soybean Proteins (1) · apararenone (1) · finerenone (1) · pamrevlumab (1) · pirfenidone (1)
Tanabe Pharma Corporation (2) · Bayer (1) · Concert Pharmaceuticals (1) · Eli Lilly and Company (1) · Glycadia (1) · Icahn School of Medicine at Mount Sinai (1) · Kyntra Bio (1) · Mesoblast, Ltd. (1) · National Center for Complementary and Integrative Health (NCCIH) (1) · Sharma, Kumar, M.D. (1) · Sunshine Lake Pharma Co., Ltd. (1) · Tongji Hospital (1)
United States (6) · China (2) · Japan (2) · Australia (1) · Bulgaria (1) · Germany (1)
Masaomi Nangaku, Professor (2) · Gregory Tracey, MD (1) · Helen Vlassara, MD (1) · K Segal, PhD (1) · Kazuoki Kondou, Adviser (1) · Kazuoki Kondou, Adviļ½er (1) · Kumar Sharma, M.D. (1) · Laurence Kennedy, M.D. (1) · Lis Cohen, D.O. (1) · Maria del Pilar Solano, M.D. (1) · Paolo Fanti, MD (1)
R01DK063017 (1)